See Full Document Text
jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99
vlk/kj.k
EXTRAORDINARY
Hkkx II—[k.M 3—mi&[k.M (ii)
PART II—Section 3—Sub-section (ii)
izkf/dkj ls izdkf'kr
PUBLISHED BY AUTHORITY
la- 2489] ubZ fnYyh] cq/okj] tqykbZ 4] 2018@vk"kk<+ 13] 1940
No. 2489] NEW DELHI, WEDNESDAY, JULY 4 2018/ ASHADHA 13, 1940
jlk;u vkSj moZjd ea=ky;
¼ vkS"k/k foHkkx½
¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½
vkns’k
ubZ fnYyh] 4 जुलाई] 2018
dk- vk-3240¼v½-& Hkkjr ljdkj d s jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 eb]Z 2013
vkSj dk- vk- 701¼v½ rkjh[k 10 ekp]Z 2016 d s lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 d s iSjk 5] 11 vkSj 15 }kjk
inz Rr 'kfDr;k sa dk i;z kxs djrs g,q ] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftldk s lfa{kIr :i e sa ,uihih, dgk tkrk g½S]
uhp s dh lkj.kh d s LrHa k ¼6½ e as fofufn"ZV [knq jk ewY; dk s mDr lkj.kh d s LrHa k ¼3½] ¼4½] vkSj ¼5½ e as rRLFkkuh ifzof"V;ksa e sa
fofufn"ZV icz yrk] bdkb Z ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;k sa d s uke lfgr LrHa k ¼2½ e sa dh rRLFkkuh izfof"V es a l s
iRz ;ds dh] oLr q ,o a lsok dj] ;fn dkbs Z gS] dk s NkMs d+ j vf/kdre [knq jk ewY; d s :i e sa fu;r djrh gSA
lkj.kh
dz- vuqlwfpr fofufeZfr dk izcyrk bdkbZ fofuekZrk vkSj foi.ku [kqnjk ewY;
la- uke@czkaM dk uke daiuh ¼#-½
(1) (2) (3) (4) (5) (6)
1. jkstwokLVkfVu $ izR;sd gkMZ tsysVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 16.73
DyksfiMksxzsy dSIlwy jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj QkekZL;wfVdYl fy-@bfjt
¼ØsokLV lhoh 20½ jkstwokLVkfVu 20 fexzk-] ykbQlkbalsl fy-
DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj
DyksfiMksxzsy 75 fexzk-
2. Q~ywdksuktksy izR;sd vfyfir xksyh esa% 1 xksyh eSllZ ,Des QkWewZys’ku izk-fy- 6.24
fMLijflcy xksyh Q~ywdksuktksy vkbZih 50 fexzk- @eSllZ lu QkekZL;wfVdYl
¼vyVhdsu&50 MhVh½ baMLVªht fy-
3. ,eksDlhlhfyu $ izR;sd 5 fefy- iqufufeZr fuyacu esa% 1 fefy- eSllZ xSYQk yScksjsVjhr fy- 3.219
DykoqyusV MªkbZ flji ,eksDlhlhfyu VªhgkbMªsV vkbZih ds cjkcj
¼DykuksDlh QkWVZ½ ,eksDlhlyfyu 400 fexzk-]
iksVsf’k;e DykoqyusV fMyqfVM vkbZih ds
cjkcj Dykoqyfud ,flM 57 fexzk-
3776 GI/2018 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
4. VsyfelkVZu $ izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ jsosuHksy ck;ksVsd fy- 11.05
esVksizksyksy xksyh VsyfelkVZu vkbZih 40 fexzk-]
/ eSllZ िस(cid:4)ला fy-
¼esVksykj Vh,y 25½ esVksizksyksy lqlkbusV vkbZih 47-50 fexzk-
ds cjkcj esVksizksyksy VkjVªsV 50 fexzk-
¼bZvkj½
5. VsyfelkVZu $ izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ jsosuHksy ck;ksVsd 9.22
esVksizksyksy xksyh VsyfelkVZu vkbZih 40 fexzk-]
fy- / eSllZ िस(cid:4)ला fy-
¼esVksykj Vh,y 25½ esVksizksyksy lqlkbusV vkbZih 23-50 fexzk-
ds cjkcj esVksizksyksy VkjVªsV 25 fexzk-
¼bZvkj½
6. gkbMªksDlhDyksjksDohu izR;sd fQYe fyfir xksyh es% 1 xksyh eSllZ okysl 9.58
lYQsV xksyh gkbMªksDlhDyksjksDohu lYQsV 300 fexzk- QkekZL;wfVdYl izk- fy-
¼vks,DllhD;w 300 fexzk-½
7. XyhesfijkbM $ esVQksfeZu izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ fLol xkfuZ;j 6.89
xksyh XyhesfijkbM 3 fexzk-] tsusfDl;k lkbalst@ eSllZ
esVQksfeZu ,lvkj 500 fexzk- XysuekdZ QkekZL;wfVdYl fy-
8. XyhesfijkbM $ esVQksfeZu izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ fLol xkfuZ;j 11.01
$ oksXyhcksl xksyh XyhesfijkbM 2 fexzk-] tsusfDl;k lkbalst@ eSllZ
esVQksfeZu ,lvkj 500 fexzk- XysuekdZ QkekZL;wfVdYl
oksXyhcksl 0-3 fexzk- xksyh fy-
9. XyhesfijkbM $ esVQksfeZu izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ fLol xkfuZ;j 11.61
$ oksXyhcksl xksyh XyhesfijkbM 2 fexzk-] tsusfDl;k lkbalst@ eSllZ
esVQksfeZu ,lvkj 1000 fexzk- XysuekdZ QkekZL;wfVdYl
oksXyhcksl 0-2 fexzk- xksyh fy-
10. XyhesfijkbM $ esVQksfeZu izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ fLol xkfuZ;j 9.40
$ oksXyhcksl xksyh XyhesfijkbM 1 fexzk-] tsusfDl;k lkbalst@ eSllZ
esVQksfeZu ,lvkj 500 fexzk- XysuekdZ QkekZL;wfVdYl
oksXyhcksl 0-3 fexzk- xksyh fy-
11. VsyfelkVZu $ izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ fLol xkfuZ;j 10.37
fdYuhMhikbu $ VsyfelkVZu vkbZih 40 fexzk-] tsusfDl;k lkbalst@ eSllZ
DyksjFkkyhMksu xksyh fdYuhMhikbu 10 fexzk- vkSj XysuekdZ QkekZL;wfVdYl
DyksjFkkyhMksu vkbZih 6-25 fexzk- fy-
12. Dyksuktsike $ izR;sd vfyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 4.12
izksizkuksyksy xksyh Dyksuktsike vkbZih 0-50 fexzk-] QkekZL;wfVdYl fy-@eSllZ
izksizkuksyksy gkbMªksDyksjkbM vkbZih 20 ,eD;ksj QkekZL;wfVdYl fy-
fexzk-
13. VsyfelkVZu $ izR;sd fQYe fyfir fcys;MZ xksyh esa% 1 xksyh eSllZ QkekZQscfjdksu 5.89
DyksjFkkyhMksu xksyh VsyfelkVZu vkbZih 40 fexzk-]
¼VsyQk&lh,p½ DyksjFkkyhMksu vkbZih 12-5 fexzk-
14. MksDlks:fclhu izR;sd fefy- esa% 10 fefy- eSllZ ukVdks QkekZ fy- 6459.20
gkbMªksDyksjkbM fyikslkse MksDlks:fclhu gkbMªksDyksjkbM 2 fexzk- ok;y @eSllZ vksjs,V gsYFk izk-
batSD’ku 20 fexzk-@ ¼isxhysfVM fyikslkseky½ okVj QkWj fy-
fefy- ¼20 fexzk-@ok;y½ batSD’ku
10 fefy- ¼isthysfVM
fyikslksey½ dulUVªsV
QkWj buQ~;wtu
15. fdYuhMhikbu $ fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 4.00
VsyfelkVZu xksyh fdYuhMhikbu vkbZih 10 fexzk-] QkekZL;wfVdYl fy- eSllZ
¼flYuhCyw Vh½ VsyfelkVZu vkbZih 40 fexzk- Cyw Øksl yscksjsVjht izk-
fy-
16. lksQkslcqfoj $ izR;sd fQYe fyfir xksyh esa% 28 eSllZ ukVdks QkekZ fy-@ 15481.86
osyiVlohj xksyh lksQkslcqfoj 400 fexzk-] xksfy;ka eSllZ ,izktj gsYFk ds;j
osyiVlohj 100 fexzk- izk-fy-
17. lksQkslcqohj $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ukVdks QkekZ fy-@ 589.92
lksQkslcqfoj 400 fexzk-] eSllZ ,izktj gsYFk ds;j
लेड(cid:9)पासवीर xksyh
izk-fy-
लेड(cid:9)पासवीर 90 fexzk-
18. bVksfjdksDlho $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ dSfMyk 5.46
iSjkflVkeksy xksyh bVksfjdksDlho 60 fexzk-] QkekZL;wfVdYl fy-
iSjkflVkeksy 325 fexzk-
19. ,Mkiysu $ csutks,y ‘kkfey gSa% 1 xzke eSllZ ,isDl yscksjsVjht 18.42
tSy ,Mkiysu chih 0-1% MCY;w@MCY;w izk- fy-
csutks,y ijvkDlkbM vkbZih ds cjkcj
,ugkbMªkst csutks,y isjksDlkbM 2-5%
MCY;w@MCY;w
20 VsusfyfXyfIVu $ izR;sd vfyfir fcys;j xksyh esa% 1 xksyh eSllZ lk;uksdse 10.09
esVQksfeZu xksyh VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds QkekZL;wfVdYl fy-@eSllZ¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3
¼okykQst Vh 500½ cjkcj VsusfyfXyfIVu 20 fexzk-] oSySl QkekZL;wfVdYl izk-
esVQksfeZu ,plh,y 1000 fexzk- ¼,lvkj½ fy-
21. VsusfyfXyfIVu $ izR;sd vfyfir fcys;j xksyh esa% 1 xksyh eSllZ lk;uksdse 9.79
esVQksfeZu xksyh VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds QkekZL;wfVdYl fy-@eSllZ
¼okykQst Vh 500½ cjkcj VsusfyfXyfIVu 20 fexzk-] oSySl QkekZL;wfVdYl izk-
esVQksfeZu ,plh,y 500 fexzk- ¼,lvkj½ fy-
22. fczeksfuMkbu $ fVeksyksy ‘kkfey gSa% 1 fefy- eSllZ ,dEl MªXl ,aM 18.75
vkbZ MªksIl ¼U;w ,yczhe fczeksfuMkbu VkjVªkV vkbZih 0-2% QkekZL;wfVdYl fy-@eSllZ
,y,lVh½ MCY;w@oh fVeksyksy ds cjkcj fVeksyksy ,ysefcd QkekZL;wfVDyl
5% MCY;w@oh LVsfjy ,D;w,vksl fy-
osfgdy D;w-,l
23. XyhesfijkbM $ esVQksfeZu izR;sd संशोिधत fcys;MZ xskyh esa% 1 xksyh eSllZ vaQj 6.89
$ xksyh ¼XykbdksesV vkWxsZfuDl@eSllZ ;w,loh
XyhesfijkbM vkbZih 3 fexzk-]
thih 3½ izk- fy-
esVQksfeZu gkbMªksDyksjkbM vkbZih 500
fexzk- ¼bZvkj½
24. iSdyhVkDlsy ¼izksVhu izR;sd ok;y esa% izfr iSd eSllZ fcVk MªXl fy- 11590.00
ckmaM ikfVZdYl½ QkWj iSdyhVkDlsy vkbZih 100 fexzk-@ok;y @eSllZ vkjihth ykbQ
butsDVsfcy lLisa’ku lkbalst fy-
yb;ksfQfytsM g~;qeu ए(cid:20)बिमन D;w-,l.
25. XyhesfijkbM $ esVQksfeZu izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ ;wuhlu 1.79
$ xksyh ¼Xyhfelu&,e XyhesfijkbM vkbZih 0-5 fexzk- vkSj QkekZL;wfVdYl fy-
0-5½
esVQksfeZu ,plh,y vkbZih 500 fexzk-
¼izksykWxM jhfyt QkWeZ esa½
26. VsusfyfXyfIVu $ izR;sd vfyfir fcys;j xksyh esa% 1 xksyh eSllZ lk;uksdse 9.50
esVQksfeZu xksyh ¼VsusCyw VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds QkekZL;wfVdYl fy-@eSllZ
,e QkWVZ½ cjkcj VsusfyfXyfIVu 20 fexzk-] Cyw Øksl yscksjsVjht izk-
esVQksfeZu ,plh,y 1000 fexzk- ¼,lvkj½ fy-
27. VsusfyfXyfIVu $ izR;sd vfyfir fcys;j xksyh esa% 1 xksyh eSllZ lk;uksdse 7.50
esVQksfeZu xksyh ¼VsusCyw VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds QkekZL;wfVdYl fy-@eSllZ
,e½ cjkcj VsusfyfXyfIVu 20 fexzk-] Cyw Øksl yscksjsVjht izk-
esVQksfeZu ,plh,y 500 fexzk- ¼,lvkj½ fy-
28. vksyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ I;ksj ,aM D;ksj 12.95
,eyksfMikbu $ vksyfelkVZu esMksDlksfey vkbZih 40 gsYFkds;j izk- fy-@eSllZ
gkbZMªksDyksjksFkkbtkbM fexzk-] esudkbaM QkekZ fy-
xksyh ¼,eyksdkbaM&5) ,eyksfMikbu fclkbysV vkbZih ds cjkcj
,eyksfMikbu 5 fexzk- vkSj
gkbZMªksDyksjksFkkbtkbM vkbZih 12-5
29. VªkoksizksLV $ fVeksyksy ‘kkfey gSa% 1 fefy- eSllZ I;ksj ,aM D;ksj 130.76
ekys,V $ VªkoksizksLV vkbZih 0-004% MCY;w@oh] gsYFkds;j izk- fy-@eSllZ
fcutkydksfu;e vkbZ fVeksyksy ekys,V vkbZih ds cjkcj ykbQ LVkj QkekZ izk- fy-
MªksIl fVeksyksy 0-5% MCY;w@oh]
fcutkydksfu;e DyksjkbM lksyq’ku
vkbZih 0-01% oh@oh
30. czheksfuMkbu $ fVeksyksy ‘kkfey gSa% 1 fefy- eSllZ I;ksj ,aM D;ksj 21.68
ekys,V fcutkYdksfu;e czheksfuMkbu VkjVªkV vkbZih 0-2% gsYFkds;j izk- fy-@eSllZ
vkbZ MªksIl MCY;w@oh] ykbQ LVkj QkekZ izk- fy-
fVeksyksy ekys,V vkbZih ds cjkcj
fVeksyksy 0-5% MCY;w@oh]
fcutkydksfu;e DyksjkbM lksyq’ku
vkbZih 0-01% oh@oh
31. VsusfyfXyfIVu $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ XysuekdZ 10.06
esVQksfeZu xksyh VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds QkekZL;wfVdYl fy-@eSllZ
¼Xyhihtc ,e QkWVZ½ cjkcj VsusfyfXyfIVu 20 fexzk-] tqfcysaV ykbQlkbalst fy-
esVQksfeZu ,plh,y 1000 fexzk- ¼bZvkj½
32. VsusfyfXyfIVu $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ XysuekdZ 9.79
esVQksfeZu xksyh VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds QkekZL;wfVdYl fy-@eSllZ
¼Xyhihtc ,e½ cjkcj VsusfyfXyfIVu 20 fexzk-] tqfcysaV ykbQlkbalst fy-
esVQksfeZu ,plh,y 500 fexzk- ¼bZvkj½
33. VsusfyfXyfIVu $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ ;wuhlu 6.25
esVQksfeZu xksyh VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds QkekZL;wfVdYl izk- fy-
cjkcj VsusfyfXyfIVu 20 fexzk-]
esVQksfeZu ,plh,y 1000 fexzk- ¼bZvkj½
34. VsusfyfXyfIVu $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ ;wuhlu 5.358
esVQksfeZu xksyh VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds QkekZL;wfVdYl izk- fy-4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
cjkcj VsusfyfXyfIVu 20 fexzk-]
esVQksfeZu ,plh,y 500 fexzk- ¼bZvkj½
35. VªkoksizksLV $ fVeksyksy izR;sd fefy- esa% 1 fefy- eSllZ ,dEl MªXl ,aM 86.30
vkbZ MªksIl VªkoksizksLV vkbZih 40 ,elhth] QkekZL;wfVdYl fy-@eSllZ
¼VªkfolkbV&Vh½ fVeksyksy ekys,V vkbZih ds cjkxj ,ysefcd QkekZL;wfVdYl
fVeksyksy 5 fexzk- fy-
36. fdYuhMhikbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ lQsVc ykbQ 10.37
VsyfelkVZu fdYuhMhikbu 10 fexzk-] lkbal@eSllZ yqfiu fy-
DyksjFkkyhMksu xksyh VsyfelkVZu vkbZih 40 fexzk-]
DyksjFkkyhMksu 6-25 fexzk-
37. VsyfelkVZu $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ QkekZQscfjdksu 7.14
gkbMªksDyksjFkkbtkbM VsyfelkVZu vkbZih 40 fexzk-]
xksyh ¼VsYQk&,p½ gkbMªksDyksjFkkbtkbM vkbZih 12-5 fexzk-
38. Qsjl ,LdkscsZV $ Qksfyd izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ fr:ifr esfMds;j 8.89
,flM xksyh Qsjl ,LdkscsZV ds cjkcj bysesuVy fy-@eSllZ tsMl dSfMyk
vk;ju 100 fexzk-] gsYFkds;j fy-
Qksfyd ,flM vkbZih 1-5 fexzk-
39. MksDlks:fcflu izR;sd fefy- esa% 25 fefy- eSllZ ukVdks QkekZ fy- 13473.68
gkbMªksDyksjkbM batSD’ku MksDlks:fcflu gkbMªksDyksjkbM vkbZih 2 ok;y @eSllZ tsMl dSfMyk
fexzk- ¼fixkbysfVM fyikslksey½ okVj gsYFkds;j fy-
QkWj batSD’ku
40. jkstwokLVkfVu $ izR;sd gkMZ tsysVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 16.26
DyksfiMksxzsy dSIlwy jkstwokLVkfVu vkbZih 20 fexzk- ¼iSysVl QkekZL;wfVdYl fy-@eSllZ
esa½] baVkl QkekZL;wfVdYl fy-
DyksfiMksxzsy vkbZih 75 fexzk- ¼iSysVl esa½
41. fdYuhMhikbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ esdysM~l 7.67
VsyfelkVZu xksyh fdYuhMhikbu 10 fexzk- vkSj QkekZL;wfVdYl fy-
¼usDlkso ,,l Vh½ VsyfelkVZu vkbZih 40 fexzk-
42. fdYuhMhikbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 7.14
VsyfelkVZu xksyh fdYuhMhikbu 10 fexzk- vkSj QkekZL;wfVdYl fy-@eSllZ
¼thVsyeh&lh,y½ VsyfelkVZu vkbZih 40 fexzk- ,QMhlh fy-
43. fMDyksQsud $ fyulhM ‘kkfey gSa% 1 xzke eSllZ VqVksu 1.40
vkW;y $ esFkkby fMDyksQsud MkbbfFkykekbu 1-16% QkekZL;wfVdyl@eSllZ
lsfylkbysV $ esaFkksy $ MCY;w@MCY;w$ fyulhM vkW;y 3% ;wuhlu QkekZL;wfVdYl izk-
csutkby ,Ydksgy tSy MCY;w@MCY;w $ esFkkby lkyhlkbysV fy-
¼Mu½
10% MCY;w@MCY;w $ esaFkksy 5%
MCY;w@MCY;w csutkby ,Ydksgy 1%
MCY;w@MCY;w tSy csl D;w-,l
44. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ;wuhlu 2.99
,EyksfMikbu xksyh VsyfelkVZu vkbZih 40 fexzk-] QkekZL;wfVdYl izk- fy-
¼VsyehjkbM& ,,e½ ,EyksfMikbu 5 fexzk-
45. fdYuhMhikbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ foaMykl ck;ksVsd izk- 3.57
VsyfelkVZu xksyh fdYuhMhikbu 10 fexzk- vkSj fy- / eSllZ ;wuhlu
¼VsyehjkbM& ,y,u½ VsyfelkVZu vkbZih 40 fexzk- QkekZL;wfVdYl izk- fy-
46. oksXyhcksl $ esVQksfeZu izR;sd fcys;MZ xksyh esa% 1 xksyh eSllZ ;wuhlu 3.20
xksyh$ ¼oksXyhlksu&,e 0- oksXyhcksl 0-2 fexzk- vkSj QkekZL;wfVdYl izk- fy-
2½ esVQksfeZu gkbMªksDyksjkbM 500 fexzk-
47. oksXyhcksl $XyhesfijkbM izR;sd xksyh esa% 1 xksyh eSllZ foaMykl ck;ksVsd izk- 9.37
esVQksfeZu xksyh$ oksXyhcksl vkbZih 0-3 fexzk-] fy-@eSllZ isufl;k
¼chVkXyhe 2 ,eoh 0-3½ XyhesfijkbM vkbZih 2 fexzk- vkSj ck;ksVsd fy-
esVQksfeZu ¼,lvkj½ 500 fexzk-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5
48. oksXyhcksl $XyhesfijkbM izR;sd xksyh esa% 1 xksyh eSllZ foaMykl ck;ksVsd izk- 8.03
esVQksfeZu xksyh$ oksXyhcksl vkbZih 0-3 fexzk-] fy-@eSllZ isufl;k
¼chVkXyhe 1 ,eoh 0-3½ XyhesfijkbM vkbZih 1 fexzk- vkSj ck;ksVsd fy-
esVQksfeZu ¼,lvkj½ 500 fexzk-
49. oksXyhcksl $XyhesfijkbM izR;sd xksyh esa% 1 xksyh eSllZ foaMykl ck;ksVsd 8.48
esVQksfeZu xksyh$ oksXyhcksl vkbZih 0-2 fexzk-] izk- fy-@eSllZ isufl;k
¼chVkXyhe 2 ,eoh½ XyhesfijkbM vkbZih 2 fexzk- vkSj ck;ksVsd fy-
esVQksfeZu ¼,lvkj½ 500 fexzk-
50. oksXyhcksl $XyhesfijkbM izR;sd xksyh esa% 1 xksyh eSllZ foaMykl ck;ksVsd 7.14
esVQksfeZu xksyh$ oksXyhcksl vkbZih 0-2 fexzk-] izk- fy-@eSllZ isufl;k
¼chVkXyhe 1 ,eoh½ XyhesfijkbM vkbZih 1 fexzk- vkSj ck;ksVsd fy-
esVQksfeZu ¼,lvkj½ 500 fexzk-
uksV %
¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds
rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA
¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku
fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA
¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr
lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY;
fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh
rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA
¼?k½vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd
fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds
bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgt n`’; Hkkx ij dher lwph vkSj iwjd lwph]
;fn dksbZ gks] dks laiznf’kZr djsxkA
¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus
vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k
Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds
vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds
rgr lacaf/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA
¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os
vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr
jkf'k dks tek djus ds fy, nk;h gksaxsA
¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh
[kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks
tk;saxsA
[dka- la-@190@58/2018@,Q@Qk- la- 8¼58½@2018@Mhih@,uihih,&fMoh-II]
cythr flag] lgk;d funs'kd
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 4th July, 2018
S. O. 3240(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein
below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in
the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer &
marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Brand Marketing Price
Name Company (Rs.)
(1) (2) (3) (4) (5) (6)
1. Rosuvastatin + Each Hard gelatine capsule contains: 1 Capsule M/s Synokem 16.73
Clopidogrel Capsule Rosuvastatin Calcium IP eq. to Pharmaceuticals Ltd/
(Crevast CV 20) Rosuvastatin 20mg, M/s Eris Lifesciences
Clopidogrel Bisulphate IP eq. to Ltd.
Clopidogrel 75mg.
2. Fluconazole Each uncoated tablet contains: 1 Tablet M/s Acme 6.24
Dispersible Tablet Fluconazole IP 50mg Formulations
(ULTICAN – 50 DT) Pvt. Ltd. / M/s Sun
Pharmaceutical
Industries Ltd.
3. Amoxycillin + Each 5ml of reconstituted 1 ML M/s Galpha 3.219
Clavulante Dry Syrup Suspension: Laboratories Limited
(Clanoxy Forte) Amoxycillin Trihydrate IP eq. to
Amoxycillin 400mg, Potassium
Clavulante Diluted IP eq. to
Clavulnic Acid 57mg
4. Telmisartan + Each film coated bilayered tablet 1 Tablet M/s Revenbhel 11.05
Metoprolol Tablet contains: Biotech Ltd./
(Metolar TL 50) Telmisartan IP 40mg, M/s Cipla Ltd.
Metoprolol Succinate IP 47.50mg eq.
to Metoprolol Tartrate 50mg (ER)
5. Telmisartan + Each film coated bilayered tablet 1 Tablet M/s Revenbhel 9.22
Metoprolol Tablet contains: Biotech Ltd. /
(Metolar TL 25) Telmisartan IP 40mg, M/s. Cipla Ltd.
Metoprolol Succinate IP 23.50mg eq.
to Metoprolol Tartrate 25mg (ER)
6. Hydroxychloroquine Each film coated tablet contains: 1 Tablet M/s Wallace 9.58
Sulphate Tablet Hydroxychloroquine Sulphate Pharmaceuticals
(OXCQ 300mg) 300mg Pvt. Ltd.
7. Glimepiride + Each film coated bilayered tablet 1 Tablet M/s Swiss Garnier 6.89
Metformin Tablet contains: Genexiaa Sciences /
Glimepiride 3mg, M/s Glenmark
Metformin SR 500mg Pharmaceuticals Ltd.
8. Glimepiride + Each film coated bilayered tablet 1 Tablet M/s Swiss Garnier 11.01
Metformin + contains: Genexiaa Sciences /
Voglibose Tablet Glimepiride 2mg, M/s. Glenmark
Metformin SR 500mg Pharmaceuticals Ltd.
Voglibose 0.3mg Tablets
9. Glimepiride + Each film coated bilayered tablet 1 Tablet M/s Swiss Garnier 11.61
Metformin + contains: Genexiaa Sciences /
Voglibose Tablet Glimepiride 2mg, M/s. Glenmark
Metformin SR 1000mg Pharmaceuticals Ltd.
Voglibose 0.2mg Tablets
10. Glimepiride + Each film coated bilayered tablet 1 Tablet M/s Swiss Garnier 9.40
Metformin + contains: Genexiaa Sciences /
Voglibose Tablet Glimepiride 1mg, M/s. Glenmark
Metformin SR 500mg Pharmaceuticals Ltd.
Voglibose 0.3mg Tablets
11. Telmisartan + Each film coated bilayered tablet 1 Tablet M/s Swiss Garnier 10.37
Clinidipine + contains: Genexiaa Sciences /
Chlorthalidone Tablet Telmisartan IP 40mg, M/s. Glenmark¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7
Clinidipine 10mg & Pharmaceuticals Ltd.
Chlorthalidone IP 6.25mg
12. Clonazepam + Each uncoated tablet contains: 1 Tablet M/s Akums Drugs & 4.12
Propranolol Tablet Clonazepam IP 0.50mg, Pharmaceutical
Propranolol Hydrochloride IP 20mg Limited / M/s
Emcure
Pharmaceuticals
Limited
13. Telmisartan + Each uncoated bilayered tablet 1 Tablet M/s 5.89
Chlorthalidone contains: Pharmafabrikon
Tablet (Telpha-CH) Telmisartan IP 40mg,
Chlorthalidone IP 12.5mg
14. Doxorubicin Each ml contains: 10 ML vial M/s Natco Pharma 6459.20
Hydrochloride Doxorubicin Hydrochloride 2mg Limited / M/s
Liposome Injection (Pegylated Liposomal) Water for Aureate Health
2mg/ml (20mg/vial) Injection Pvt. Ltd.
10ml (Pegylated
Liposomal)
Concentrate for
Infusion
15. Cilnidipine + Each film coated tablet contains: 1 Tablet M/s Akums Drugs 4.00
Telmisartan Tablet Cilnidipine IP 10mg, & Pharmaceuticals
(Cilniblu T) Telmisartan IP 40mg Ltd. / M/s Blue
Cross Laboratories
Pvt. Ltd.
16. Sofosbuvir + Each film coated tablet contains: 28’s Tablets M/s Natco Pharma 15481.86
Velpatsvir Tablet Sofosbuvir 400mg, Ltd. / M/s Aprazer
Velpatsvir 100mg Health Care Pvt.
Ltd.
17. Sofosbuvir + Each film coated tablet contains: 1 Tablet M/s Natco Pharma 589.92
Ledipasvir Tablet Sofosbuvir 400mg, Ltd. / M/s Aprazer
Ledipasvir 90mg Health Care Pvt.
Ltd.
18. Etoricoxib + Each film coated tablet contains: 1 Tablet M/s Cadila 5.46
Paracetamol Tablet Etoricoxib 60mg, Pharmaceuticals
Paracetamol 325mg Limited
19. Adapalene + Benzoyl Contains: 1 GM M/s Apex 18.42
Gel Adapalene BP 0.1% w/w Laboratories Private
Benzoyl Peroxide IP eq. to Limited
Anhydrous Benzoyl Peroxide
2.5%w/w
20 Teneligliptin + Each uncoated bilayer tablet 1 Tablet M/s Synokem 10.09
Metformin Tablet contains: Pharmaceuticals Ltd.
(Walaphage T 1000) Teneligliptin Hydrobromide Hydrate / M/s Wallace
eq. to Teneligliptin 20mg Pharmaceuticals Pvt.
Metformin HCl 1000mg (SR) Ltd.
21. Teneligliptin + Each uncoated bilayer tablet 1 Tablet M/s Synokem 9.79
Metformin Tablet contains: Pharmaceuticals Ltd.
(Walaphage T 500) Teneligliptin Hydrobromide Hydrate / M/s Wallace
eq. to Teneligliptin 20mg Pharmaceuticals Pvt.
Metformin HCl 500mg (SR) Ltd.
22. Brimonidine + Contains: 1 ML M/s Akums Drugs & 18.75
Timolol Eye Drops Brimonidine Tartrate IP 0.2%w/v, Pharmaceuticals Ltd.
(New Albrim LST) Timolol Maleate IP eq. to Timolol / M/s Alembic
0.5% w/v Sterile aqueous vehicle q.s. Pharmaceuticals
Limited8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
23. Glimiepiride + Each modified bi-layered ed tablet 1 Tablet M/s Anphar 6.89
Metformin Tablet contains: Organics. / M/s USV
(GLYCOMET GP 3) Glimiepiride IP 3mg, Private Limited
Metformin Hydrochloride IP 500mg
(ER)
24. Paclitaxel (Protein Each vial contains: Each Pack M/s Beta Drugs Ltd / 11590.00
bound Particles) for Paclitaxel IP 100mg/vial Lyophilized M/s RPG Life
Injectable Suspension Human albumin q.s. Sciences Limited
25. Glimiepiride + Each Uncoated bilayered Tablet 1 Tablet M/s Unison 1.79
Metformin Tablet contains: Pharmaceuticals
(Glimison – M 0.5) Glimepiride IP 0.5mg & Metformin Limited
HCL IP 500mg (in prolonged release
form)
26. Teneligliptin + Each uncoated bilayer tablet 1 Tablet M/s Synokem 9.50
Metformin Tablet contains: Pharmaceuticals Ltd.
(Teneblu M Forte) Teneligliptin Hydrobromide Hydrate / M/s Blue Cross
eq. to Teneligliptin 20mg Laboratories Pvt.
Metformin HCl 1000mg (SR) Ltd.
27. Teneligliptin + Each uncoated bilayer tablet 1 Tablet M/s Synokem 7.50
Metformin Tablet contains: Pharmaceuticals Ltd.
(Teneblu M) Teneligliptin Hydrobromide Hydrate / M/s Blue Cross
eq. to Teneligliptin 20mg Laboratories Pvt.
Metformin HCl 500mg (SR) Ltd.
28. Olmesartan + Each film coated tablet contains: 1 Tablet M/s Pure & Cure 12.95
Amlodipine + Olmesartan Medoxomil IP 40mg, Healthcare Pvt. Ltd. /
Hydrochlorothiazide Amlodipine Besilate IP eq. to M/s Mankind
Tablet (Amlokind – Amlodipine 5mg & Pharma Limited
5) Hydrochlorothiazide IP 12.5
29. Travoprost + Timolol Contains: 1 ML M/s Pure & Cure 130.76
Maleate + Travoprost IP 0.004%w/v, Healthcare Pvt. Ltd. /
Benzalkonium Eye Timolol Maleate IP eq. to Timolol M/s LifeStar Pharma
Drops 0.5% w/v, Private Limited
Benzalkonium Chloride Solution IP
0.01% v/v
30. Brimonidine + Contains: 1 ML M/s Pure & Cure 21.68
Timolol Maleate + Brimonidine Tartrate IP 0.2%w/v, Healthcare Pvt. Ltd. /
Benzalkonium Eye Timolol Maleate IP eq. to Timolol M/s LifeStar Pharma
Drops 0.5% w/v, Private Limited
Benzalkonium Chloride Solution IP
0.02% v/v
31. Teneligliptin + Each uncoated bilayered tablet 1 Tablet M/s Glenmark 10.06
Metformin Tablet contains: Pharmaceuticals Ltd.
(Glipijub M Forte) Teneligliptin Hydrobromide Hydrate / M/s Jubilant
eq. to Teneligliptin 20mg Lifesciences Limited
Metformin HCl 1000mg (ER)
32. Teneligliptin + Each uncoated bilayered tablet 1 Tablet M/s Glenmark 9.79
Metformin Tablet contains: Pharmaceuticals Ltd.
(Glipijub M) Teneligliptin Hydrobromide Hydrate / M/s Jubilant
eq. to Teneligliptin 20mg Lifesciences Limited
Metformin HCl 500mg (ER)
33. Teneligliptin + Each uncoated bilayered tablet 1 Tablet M/s Unison 6.25
Metformin Tablet contains: Pharmaceuticals Pvt.
Teneligliptin Hydrobromide Hydrate Ltd.
eq. to Teneligliptin 20mg
Metformin HCl 1000mg (ER)
34. Teneligliptin + Each uncoated bilayered tablet 1 Tablet M/s Unison 5.358
Metformin Tablet contains: Pharmaceuticals Pvt.
Teneligliptin Hydrobromide Hydrate Ltd.
eq. to Teneligliptin 20mg
Metformin HCl 500mg (ER)¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9
35. Travoprost + Timolol Each ml contains: 1 ML M/s Akums Drugs & 86.30
Eye Drops Travoprost IP 40mcg, Pharmaceuticals Ltd.
(Travisight –T) Timolol Maleate IP eq. to Timolol / M/s Alembic
5mg Pharmaceuticals Ltd.
36. Cilnidipine + Each filmcoated tablet contains: 1 Tablet M/s Safetab Life 10.37
Telmisartan + Cilnidipine 10mg, Science / M/s Lupin
Chlorthalidone Tablet Telmisartan IP 40mg, Limited
Chlorthalidone 6.25mg
37. Telmisartan + Each uncoated bilayered tablet 1 Tablet M/s Pharmafabrikon 7.14
Hydrochlorthiazide contains:
Tablet (Telpha-H) Telmisartan IP 40mg,
Hydrochlorthiazide IP 12.5mg
38. Ferrous Ascorbate + Each film coated tablet contains: 1 Tablet M/s Tirupati 8.89
Folic Acid Tablet Ferrous Ascorbate eq. to Elemental Medicare Ltd / M/s
Iron 100mg, Zydus Cadila
Folic Acid IP 1.5mg, Healthcare Limited
39. Doxorubicin Each ml contains: 25 ML vial M/s Natco Pharma 13473.68
Hydrochloride Doxorubicin Hydrochloride IP 2mg Ltd. / M/s Zydus
Injection (As pegylated liposomal) Water for Cadila Healthcare
Injection Limited
40. Rosuvastation + Each hard gelatine capsule contains: 1 Capsule M/s Synokem 16.26
Clopidogrel Capsule Rosuvastation IP 20mg (As pellets), Pharmaceuticals
Clopidogrel IP 75mg (as pellets) Limited / M/s
INTAS
Pharmaceuticals
Limited
41. Cilnidipine + Each film coated tablet contains: 1 Tablets M/s Macleods 7.67
Telmisartan Tablet Cilnidipine 10mg & Pharmaceuticals
(NEXOVAS T) Telmisartan IP 40mg Limited
42. Cilnidipine + Each film coated tablet contains: 1 Tablets M/s Akums Drugs & 7.14
Telmisartan Tablet Cilnidipine 10mg & Pharmaceuticals
(ZITELMI –CL) Telmisartan IP 40mg Limited / M/s FDC
Limited
43. Diclofenac + Linseed contains: 1 GM M/s Tuton 1.40
Oil + Methyl Diclofenac Diethylamine 1.16% w/w Pharmaceuticals /
Salicylate + Menthol + M/s Unison
+ Benzyl Alcohol Linseed Oil 3% w/w + Pharmaceuticals Pvt.
GEL (Dan) Methyl Salicylate 10% w/w Ltd.
Menthol 5% w/w
Benzyl Alcohol 1% w/w
GEL base q. s.
44. Telmisartan + Each film coated tablets contains: 1 Tablet M/s Unison 2.99
Amlodipine Tablet Telmisartan IP 40mg + Pharmaceuticals Pvt.
(Telmiride – AM) Amlodipine 5mg Ltd.
45. Cilnidipine + Each film coated tablet contains: 1 Tablet M/s Windlas Biotech 3.57
Telmisartan Tablet Cilnidipine 10mg & Pvt. Ltd. / M/s
(Telmiride – LN) Telmisartan IP 40mg Unison
Pharmaceuticals Pvt.
Ltd.
46. Voglibose + Each uncoated bilayered tablet 1 Tablet M/s Unison 3.20
Metformin Tablet Contains: Pharmaceuticals Pvt.
(Voglyson – M 0.2) Voglibose 0.2mg & Ltd.
Metformin Hydrochloride 500mg10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
47. Voglibose + Each tablets contains: 1 Tablet M/s Windlas Biotech 9.37
Glimepiride + Voglibose IP 0.3mg, Pvt. Ltd. / M/s
Metformin Tablet Glimepiride IP 2mg & Panacea Biotech Ltd.
(BETAGLIM 2 MV Metformin (SR) 500mg
0.3)
48. Voglibose + Each tablets contains: 1 Tablet M/s Windlas Biotech 8.03
Glimepiride + Voglibose IP 0.3mg, Pvt. Ltd. / M/s
Metformin Tablet Glimepiride IP 1mg & Panacea Biotech Ltd.
(BETAGLIM 1 MV Metformin (SR) 500mg
0.3)
49. Voglibose + Each tablets contains: 1 Tablet M/s Windlas Biotech 8.48
Glimepiride + Voglibose IP 0.2mg, Pvt. Ltd. / M/s
Metformin Tablet Glimepiride IP 2mg & Panacea Biotech Ltd.
(BETAGLIM 2 MV) Metformin (SR) 500mg
50. Voglibose + Each tablets contains: 1 Tablet M/s Windlas Biotech 7.14
Glimepiride + Voglibose IP 0.2mg, Pvt. Ltd. / M/s
Metformin Tablet Glimepiride IP 1mg & Panacea Biotech Ltd.
(BETAGLIM 1 MV) Metformin (SR) 500mg
Note:
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the
DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to
the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned
manufacturer in accordance with the retail price specified in column (6) of the above table as per
provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in
Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS
and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the
supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the
premises where he carries on business in a manner so as to be easily accessible to any person wishing
to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as
mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision
as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements
as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission
from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the
concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company
shall be liable to deposit the overcharged amount along with the interest thereon under the provisions
of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above
table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the
above said date of notification, stand(s) superseded.
[PN/190/58/2018/F/ F. No. 8(58)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH,Assistant Director
vkns’k
ubZ fnYyh] rkjh[k% 4 जुलाई] 2018
dk-vk- 3241¼v½-&vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr
ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11
lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;
}kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016
ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk
iznRr ‘kfDr;ksa dk iz;ksx djrs gq, vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds
jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa]
tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr
djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh;
vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ uhps dh lkj.kh
ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa Øe’k%
rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk
¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa
lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS%
lkj.kh
dz- vuqlwfpr [kqjkd :i bdkbZ vf/kdre iqufoZyksdu vkns’k ekStwnk dk- vk-
la- fofufeZfr dk ,oa izcyrk dher la- ,oa rkjh[k la- ,oa rkjh[k
uke ¼#-½
(1) (2) (3) (4) (5) (6) (7)
1. fMxksDlhu vksjy 1 fefy- 1.19 31015/100/2017- 1461(v) fnukad
fyD;wbZM 0-05 ihvkbZ ewY; fu/kkZj.k 02.04.2018
fexzk-@fefy- dh rkjh[k
(Ø-la- 263)
07.05.2018
2. QwjkslhekbM vksjy 1 fefy- 2.60 31015/101/2017- 1461(v) fnukad
fyD;wbZM 10 ihvkbZ ewY; fu/kkZj.k 02.04.2018
fexzk-@fefy- dh rkjh[k
(Ø-la- 340)
07.05.2018
uksV %
¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks
ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks csp jgs
vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ¼/ku oLrq ,oa
lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku djsaxsA
¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V vf/kdre ewY;
dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk fofuekZrk Mhihlhvks] 2013 ds
iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd vkSj djksa ds varj ds dkj.k vf/kdre
[kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY; dks fujarj cuk, j[ksaxsA
¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku
fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA
¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvksa dks
mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy,
vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V esa
vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh
dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA
¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd
fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds
bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph]
;fn dksbZ gks] dks laiznf’kZr djsxkA12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds
fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks
mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds
rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA
¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY;
fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh
dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk
bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj vuqlwfpr fofufeZfr;ksa ds
mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV
esa Hkjdj ,uihih, dks izLrqr djsxkA
¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh
gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr
vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA
¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh
vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl
vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxsA
[dk-a l-a@190@58/2018@,Q@Qk- l-a 8¼58½@2018@Mhih@,uihih,&fMoh- II]
cythr flga ] lgk;d fun's kd
ORDER
New Delhi, 4th July , 2018
S.O. 3241(E).—In implementation of directions given in line with review orders issued by the Department
of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department
of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by
paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated
the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of
Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of
Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table
regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the
table below, except in respect of things done or omitted to be done before such supersession, the National
Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below
as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s)
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl. Name of the Dosage form Unit Ceiling Review Order Existing SO
No. Scheduled & Strength Price number and date number and date
Formulation
(Rs.)
(1) (2) (3) (4) (5) (6) (7)¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13
1. Digoxin Oral Liquid 1 ML 1.19 31015/100/2017- 1461(E) dated
0.05mg/ml Pricing dated 02.04.2018 (at Sl.
07.05.2018 No. 263)
2. Furosemide Oral Liquid 1 ML 2.60 31015/101/2017- 1461(E) dated
10mg/ml Pricing dated 02.04.2018 (at Sl.
07.05.2018 No. 340)
Note:
(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the
ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall
continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/190/58/2018/F/F. No. 8(58)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH, Assistant Director14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
vkns’k
ubZ fnYyh] 4 जुलाई, 2018
dk- vk- 3242(v).—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr
blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s
x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0
1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher
fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] lkj.kh ds LraHk
¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k)
ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa
ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS]
jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh
ds LraHk ¼5½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼8½ eas rRLFkkuh izfof"V;ksa
esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh
rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds
:i esa fu;r djrh gSA
lkj.kh
dz- fofufeZfr dk [kqjkd :i bdkbZ vf/kdre iqufoZyksdu vkns’k ekStwnk dk- fofuekZrk vkSj
la- uke ,oa izcyrk dher la- ,oa rkjh[k vk- la- ,oa foi.ku daiuh
¼#-½ rkjh[k
(1) (2) (3) (4) (5) (6) (7) (8)
1. ,VksjokLVkfVu izR;sd gkMZ 1 10.92 31015/09/2018- 3915(v) eSllZ foaMykl
$ DyksfiMksxzsy tsysfVu dSIlwy ewY; fu/kkZj.k dh fnukad ck;ksVsd izk-
dSIlwy dSIlwy es% fnukad 18.12.2017 fy- @ eSllZ
¼,Vksdksj lhoh ,VksjokLVkfVu 29.05.2018 (Ø-la- 50) MkW- jsM~Mht
10½ 10 fexzk-] yscksjsVjht
DyksfiMksxzsy fy-
75 fexzk-
2. ,VksjokLVkfVu izR;sd gkMZ 1 15.625 31015/09/2018- 02(v) fnukad eSllZ foaMykl
$ DyksfiMksxzsy tsysfVu dSIlwy ewY; fu/kkZj.k dh 01.01.2018 ck;ksVsd izk-
dSIlwy dSIlwy es% fnukad (Ø-la- 10) fy- @ eSllZ
¼,Vksdksj lhoh ,VksjokLVkfVu 29.05.2018 MkW- jsM~Mht
20½ 20 fexzk-] yscksjsVjht fy
DyksfiMksxzsy
75 fexzk-
3. VsyfelkVZu izR;sd fQYe 1 13.06 31015/13/2018- 02(v) fnukad eSllZ lu
DyksjFkkyhMksu fyfir xksyh xksyh ewY; fu/kkZj.k dh 01.01.2018 QkekZ
xksyh ¼fVxkVsy esa% fnukad (Ø-la- 04) yscksjsVjht
lh,p 80½ VsyfelkVZu 29.05.2018 fy-
vkbZih 80
fexzk-]
DyksjFkkyhMksu
vkbZih 12-5
fexzk-
4. lsfQDlhe izR;sd fQYe 1 10.59 31015/06/2018- 3915(v) eSllZ Fksvksu
vksQ~yksDlklhu fyfir xksyh xksyh ewY; fu/kkZj.k dh fnukad QkekZL;wfVdYl
xksyh esa% fnukad 18.12.2017 baMLVªht fy-
¼jkuhDlhe lsfQDlhe 29.05.2018 (Ø-la- 40)
Iyl½ fVªgkbMªsV ds
cjkcj¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15
lsfQDlhe
,ugkbMªkst
vkbZih 200
fexzk-
5. jkstwokLVkfVu izR;sd gkMZ 1 16.60 31015/12/2018- 02(v) fnukad eSllZ
$ DyksfiMksxzsy tsysfVu dSIlwy ewY; fu/kkZj.k dh 01.01.2018 lk;uksdse
dSIlwy dSIlwy es% fnukad (Ø-la- 14) QkekZL;wfVdYl
jkstwokLVkfVu 08.06.2018 fy-@eSllZ
dSfY’k;e bfjt
vkbZih ds ykbQlkbalst
cjkcj fy-
jkstwokLVkfVu
20 fexzk-]
DyksfiMksxzsy
ckbZlYQsV
vkbZih ds
cjkcj
DyksfiMksxzsy
75 fexzk-
6. jkstwokLVkfVu izR;sd gkMZ 1 16.06 31015/14/2018- 02(v) fnukad eSllZ
$ DyksfiMksxzsy tsysfVu dSIlwy ewY; fu/kkZj.k dh 01.01.2018 lk;uksdse
dSIlwy dSIlwy es% fnukad (Ø-la- 05) QkekZL;wfVdYl
jkstwokLVkfVu 29.05.2018 fy-@ eSllZ
dSfY’k;e tsMl
vkbZih ds gsYFkds;j fy-
cjkcj
jkstwokLVkfVu
20 fexzk-]
DyksfiMksxzsy
ckbZlYQsV
vkbZih ds
cjkcj
DyksfiMksxzsy
75 fexzk-
uksV %
¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds
rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA
¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku
fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA
¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr
lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY;
fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh
rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA
¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd
fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds
bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph]
;fn dksbZ gks] dks laiznf’kZr djsxkA
¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mi;qZDr
tsusjfd@leku lajpuk okyk dksbZ Hkh czkaM@ lacaf/kr fofufeZfr;ksa dh izcyrk rFkk ljdkj }kjk fu/kkZfjr ykxw
oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr dsUnzh;@jkT; ykblsflax16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr fuekZrk@foi.ku
dEifu;ka tks vuqikyu djrh gSA
¼N½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os
vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr
jkf'k dks tek djus ds fy, nk;h gksaxsA
[dka- la-@190@58/2018@,Q@Qk- la0 8¼58½@2018@Mhih@,uihih,&fMoh-II]
cythr flag] lgk;d funs'kd
ORDER
New Delhi, the 4th July , 2018
S. O. 3242 (E).—In implementation of directions given in line with review orders issued by the Department of
Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of
Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by
paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and
S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and
in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National
Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as
the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding
entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company , as
specified in the corresponding entries in columns (3), (4) and (8) thereof;
TABLE
Sl. Name of the Dosage form & Unit Retail Review Order Existing SO Manufacturer &
No. Formulation Strength Price number and number & Marketing
(Rs.) date date Company
respectively
(1) (2) (3) (4) (5) (6) (7) (8)
1. Atorvastatin + Each hard gelatin 1 10.92 31015/09/2018- 3915(E) dated M/s Windlas Biotech
Clopidogrel capsule contains: Capsule Pricing dated 18.12.2017 Pvt. Ltd. / M/s Dr.
Capsule Atorvastatin 10mg 29.05.2018 (at Sl. No. 50) Reddy’s
(Atocor CV 10) Clopidogrel 75mg Laboratories Ltd.
2. Atorvastatin + Each hard gelatin 1 15.625 31015/09/2018- 02(E) dated M/s Windlas Biotech
Clopidogrel capsule contains: Capsule Pricing dated 01.01.2018 Pvt. Ltd. / M/s Dr.
Capsule Atorvastatin 20mg 29.05.2018 (at Sl. No. 10) Reddy’s
(Atocor CV 20) Clopidogrel 75mg Laboratories Ltd.
3. Telmisartan + Each film coated tablet 1 13.06 31015/13/2018- 02(E) dated M/s Sun Pharma
Chlorthalidone contains: Tablet Pricing dated 01.01.2018 Laboratories Limited
Tablet Telmisartan IP 80mg 29.05.2018 (at Sl. No. 04)
(Tigatel CH 80) Chlorthalidone IP
12.5mg
4. Cefixime + Each film coated tablet 1 10.59 31015/6/2018- 3915(E) dated M/s Theon
Ofloxacin contains: Tablet Pricing dated 18.12.2017 Pharmaceuticals
Tablet Cefixime Trihydrate 29.05.2018 (at Sl. No. 40) Limited / M/s Sun
(Ranixime eq. to Cefixime Pharmaceutical
Plus) anhydrous IP 200mg, Industrial Limited
Ofloxacin IP 200mg
5. Rosuvastatin + Each hard gelatin 1 16.60 31015/12/2018- 02(E) dated M/s Synokem
Clopidogrel capsule contains: Capsule Pricing dated 01.01.2018 Pharmaceuticals Ltd.
Capsule Rosuvastatin Calcium 08.06.2018 (at Sl. No. 14) / M/s Eris
IP eq. to Rosuvastatin Lifesciences Limited
20mg,
Clopidogrel¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 17
Bisulphate IP eq. to
Clopidogrel 75mg
6. Rosuvastatin + Each hard gelatin 1 16.06 31015/14/2018- 02(E) dated M/s. Synokem
Clopidogrel capsule contains: Capsule Pricing dated 01.01.2018 Pharmaceuticals Ltd.
Capsule Rosuvastatin Calcium 29.5.2018 (at Sl. No. 5) /
IP eq. to Rosuvastatin M/s Zydus
20mg (As pellets) Healthcare
Clopidogrel Ltd.
Bisulphate IP eq. to
Clopidogrel 75mg (As
pellets)
Note:
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013
shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail prices are applicable only to the manufacturer / marketeer as mentioned above for
generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all
the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including
manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as
may be applicable, by the concerned manufacturers/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
[PN/190/58/2018/F/F. No. 8(58)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.